Suppr超能文献

脓毒症的病理生理学

Pathophysiology of sepsis.

作者信息

Remick Daniel G

机构信息

Boston University School of Medicine, Boston, MA, USA.

出版信息

Am J Pathol. 2007 May;170(5):1435-44. doi: 10.2353/ajpath.2007.060872.

Abstract

Sepsis remains a critical problem with significant morbidity and mortality even in the modern era of critical care management. Multiple derangements exist in sepsis involving several different organs and systems, although controversies exist over their individual contribution to the disease process. Septic patients have substantial, life-threatening alterations in their coagulation system, and currently, there is an approved therapy with a component of the coagulation system (activated protein C) to treat patients with severe sepsis. Previously, it was believed that sepsis merely represented an exaggerated, hyperinflammatory response with patients dying from inflammation-induced organ injury. More recent data indicate that substantial heterogeneity exists in septic patients' inflammatory response, with some appearing immuno-stimulated, whereas others appear suppressed. Cellular changes continue the theme of heterogeneity. Some cells work too well such as neutrophils that remain activated for an extended time. Other cellular changes become accelerated in a detrimental fashion including lymphocyte apoptosis. Metabolic changes are clearly present, requiring close and individualized monitoring. At this point in time, the literature richly illustrates that no single mediator/system/pathway/pathogen drives the pathophysiology of sepsis. This review will briefly discuss many of the important alterations that account for the pathophysiology of sepsis.

摘要

即使在现代重症监护管理时代,脓毒症仍然是一个严重的问题,具有显著的发病率和死亡率。脓毒症存在多种紊乱,涉及几个不同的器官和系统,尽管对于它们各自在疾病过程中的作用存在争议。脓毒症患者的凝血系统存在严重的、危及生命的改变,目前有一种针对凝血系统成分(活化蛋白C)的获批疗法用于治疗严重脓毒症患者。以前,人们认为脓毒症仅仅代表一种过度的、高炎症反应,患者死于炎症诱导的器官损伤。最近的数据表明,脓毒症患者的炎症反应存在很大的异质性,一些患者表现为免疫刺激,而另一些患者则表现为免疫抑制。细胞变化延续了异质性的主题。一些细胞功能亢进,如长时间保持活化状态的中性粒细胞。其他细胞变化以有害的方式加速,包括淋巴细胞凋亡。代谢变化明显存在,需要密切和个体化的监测。目前,文献充分表明,没有单一的介质/系统/途径/病原体驱动脓毒症的病理生理学。本综述将简要讨论许多导致脓毒症病理生理学的重要改变。

相似文献

1
Pathophysiology of sepsis.
Am J Pathol. 2007 May;170(5):1435-44. doi: 10.2353/ajpath.2007.060872.
2
Inflammation and coagulation: implications for the septic patient.
Clin Infect Dis. 2003 May 15;36(10):1259-65. doi: 10.1086/374835. Epub 2003 May 8.
4
Definitions and pathophysiology of sepsis.
Curr Probl Pediatr Adolesc Health Care. 2013 Nov-Dec;43(10):260-3. doi: 10.1016/j.cppeds.2013.10.001.
5
[Pathophysiology of sepsis and possible influence of statins].
Dtsch Med Wochenschr. 2010 Oct;135(43):2128-32. doi: 10.1055/s-0030-1267491. Epub 2010 Oct 19.
6
New and emerging therapies for sepsis.
Ann Pharmacother. 2002 Apr;36(4):648-54. doi: 10.1345/aph.1A283.
8
Activated protein C: controversy and hope in the treatment of sepsis.
Curr Opin Investig Drugs. 2007 Nov;8(11):933-8.
9
Glucocorticoids and sepsis.
Minerva Anestesiol. 2005 Dec;71(12):759-68.

引用本文的文献

1
IL-1R2 as a Precision Therapeutic Target in Sepsis: Molecular Insights into Immune Regulation.
Curr Issues Mol Biol. 2025 Jun 6;47(6):429. doi: 10.3390/cimb47060429.
4
The physicochemical properties of lipopolysaccharide chemotypes regulate activation of the contact pathway of blood coagulation.
J Biol Chem. 2025 Jan;301(1):108110. doi: 10.1016/j.jbc.2024.108110. Epub 2024 Dec 18.
6
Analyzing the molecular mechanism of Scutellaria Radix in the treatment of sepsis using RNA sequencing.
BMC Infect Dis. 2024 Jul 12;24(1):695. doi: 10.1186/s12879-024-09589-2.
7
Phospholipid transfer protein ameliorates sepsis-induced cardiac dysfunction through NLRP3 inflammasome inhibition.
Open Med (Wars). 2024 Mar 27;19(1):20240915. doi: 10.1515/med-2024-0915. eCollection 2024.
10
Causal association of circulating cytokines with sepsis: a Mendelian randomization study.
Front Immunol. 2023 Oct 17;14:1281845. doi: 10.3389/fimmu.2023.1281845. eCollection 2023.

本文引用的文献

1
Evaluation of an intensive insulin protocol for septic patients in a medical intensive care unit.
Crit Care Med. 2006 Dec;34(12):2974-8. doi: 10.1097/01.CCM.0000248906.10399.CF.
2
Management of sepsis.
N Engl J Med. 2006 Oct 19;355(16):1699-713. doi: 10.1056/NEJMra043632.
3
Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.
N Engl J Med. 2006 Oct 19;355(16):1640-2. doi: 10.1056/NEJMp068197.
4
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.
N Engl J Med. 2006 Aug 10;355(6):581-92. doi: 10.1056/NEJMoa055137.
6
Neutrophils in development of multiple organ failure in sepsis.
Lancet. 2006 Jul 8;368(9530):157-69. doi: 10.1016/S0140-6736(06)69005-3.
8
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality.
J Exp Med. 2006 Jun 12;203(6):1447-58. doi: 10.1084/jem.20060375. Epub 2006 May 15.
9
The systemic inflammatory response syndrome.
Microbes Infect. 2006 Apr;8(5):1382-9. doi: 10.1016/j.micinf.2005.12.016. Epub 2006 Mar 23.
10
Inflammation and the activated protein C anticoagulant pathway.
Semin Thromb Hemost. 2006 Apr;32 Suppl 1:49-60. doi: 10.1055/s-2006-939554.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验